Children's Hospital of Fudan University
复旦大学附属儿科医院
Listed for 31 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Children's Hospital of Fudan University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatoblastoma肝母细胞瘤5 papers led
- Retinoblastoma视网膜母细胞瘤0 papers led
- Chordoma脊索瘤0 papers led
- Osteosarcoma骨肉瘤4 papers led
- Neuroblastoma神经母细胞瘤11 papers led
- Ewing sarcoma尤文肉瘤1 paper led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症0 papers led
- Beta thalassaemiaβ 地中海贫血0 papers led1 open trial led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
- Myasthenia gravis重症肌无力1 paper led
- Moyamoya disease烟雾病2 papers led
- Biliary atresia胆道闭锁21 papers led3 open trials led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
- Takayasu arteritis大动脉炎0 papers led
- Spinal muscular atrophy脊髓性肌萎缩症3 papers led
- Fabry disease法布雷病1 paper led1 open trial led
- Pompe disease庞贝病0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Behçet disease白塞病1 paper led
- Alport syndromeAlport 综合征0 papers led
- IgA nephropathyIgA 肾病2 papers led
- Gaucher disease戈谢病1 paper led
- Osteogenesis imperfecta成骨不全症1 paper led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
- Congenital diaphragmatic hernia先天性膈疝0 papers led
- Hirschsprung disease先天性巨结肠4 papers led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症2 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
- Majeed syndromeMajeed 综合征1 paper led
- NGLY1 deficiencyNGLY1 缺乏症0 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Gastrointestinal stromal tumour, Multiple myeloma, Aplastic anaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Wilson disease, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Niemann–Pick disease type C, Primary biliary cholangitis, Hereditary angioedema, Leber hereditary optic neuropathy, ISG15 deficiency.
Cancer
Hepatoblastoma
肝母细胞瘤Led 5 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 3.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for hepatoblastoma86 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy.
- YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.
- Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.
- USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway.
- ARID1B/SUB1-activated lncRNA HOXA-AS2 drives the malignant behaviour of hepatoblastoma through regulation of HOXA3.
Earlier papers (2016–2020)6
- Role of the long non‑coding RNA‑Annexin A2 pseudogene 3/Annexin A2 signaling pathway in biliary atresia‑associated hepatic injury.
- Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma.
- Distinguishing Among Pediatric Hepatoblastomas, Transitional Liver Cell Tumors, and Hepatocellular Carcinomas and Using Appropriate Chemotherapy Regimens.
- Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients.
- Long non-coding RNA-CRNDE: a novel regulator of tumor growth and angiogenesis in hepatoblastoma.
- Targeting long non-coding RNA-TUG1 inhibits tumor growth and angiogenesis in hepatoblastoma.
All its trials on ClinicalTrials.gov, any status1
Cancer
Retinoblastoma
视网膜母细胞瘤Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Shanghai for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Cancer
Chordoma
脊索瘤Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Shanghai for chordoma84 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Osteosarcoma
骨肉瘤Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
45 hospitals in Shanghai for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.
- Peri-osteosarcoma adipose computed tomography attenuation and volume for predicting chemotherapy response in pediatric patients.
- Single-cell transcriptional profiling reveals heterogeneity and developmental trajectories of Ewing sarcoma.
- Combination of ultrathin micro-patterned MXene and PEDOT: Poly(styrenesulfonate) enables organic electrochemical transistor for amperometric determination of survivin protein in children osteosarcoma.
Chinese-language papers (not in the count)1
Cancer
Neuroblastoma
神经母细胞瘤Led 11 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led11
- The Psychological Experience of Caregivers of Children With Neuroblastoma Undergoing Naxitamab Treatment: A Qualitative Study in China.
- CAMK2G Promotes Neuronal Differentiation and Inhibits Migration in Neuroblastoma.
- Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.
- Clinical impact and in vitro characterization of ADNP variants in pediatric patients.
- Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
- Circulating tumor cells in neuroblastoma: Current status and future perspectives.
- FAM201A encodes small protein NBASP to inhibit neuroblastoma progression via inactivating MAPK pathway mediated by FABP5.
- Inducible Expression of Amphinase in Neuroblastoma Cells using Cre/LoxP System.
- Incidental Neuroblastoma.
- Downregulation of MEG3 and upregulation of EZH2 cooperatively promote neuroblastoma progression.
- PHOX2B as a Reliable Marker for Neuroblastoma in Tissue and Cytology Specimens.
Earlier papers (2016–2020)16
- Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma.
- Role of long noncoding RNA in neuroblastoma.
- Mass screening for neuroblastoma in infants.
- Downregulation of MEG3 promotes neuroblastoma development through FOXO1-mediated autophagy and mTOR-mediated epithelial-mesenchymal transition.
- Circulating tumor DNA in neuroblastoma.
- TRIM59 knockdown inhibits cell proliferation by down-regulating the Wnt/β-catenin signaling pathway in neuroblastoma.
- The association between lncRNA LINC01296 and the clinical characteristics in neuroblastoma.
- Prognostic factor analysis of stage 4S neuroblastoma in infant patients: A single center study.
- Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China.
- Circulating tumor cells detection in neuroblastoma patients by EpCAM-independent enrichment and immunostaining-fluorescence in situ hybridization.
- Comparison of long-term prognosis of laparoscopic and open adrenalectomy for local adrenal neuroblastoma in children.
- Downregulation of bone morphogenetic protein receptor 2 promotes the development of neuroblastoma.
- Variable MIBG Activity in the Same Renal Cyst.
- Artemether Regulates Chemosensitivity to Doxorubicin via Regulation of B7-H3 in Human Neuroblastoma Cells.
- Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells.
- MEG3, HCN3 and linc01105 influence the proliferation and apoptosis of neuroblastoma cells via the HIF-1α and p53 pathways.
Cancer
Ewing sarcoma
尤文肉瘤Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Chinese-language papers (not in the count)1
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06764238
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06882057
Age 1 year to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT07152041
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status5
- Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led no English-language PubMed papers on haemophagocytic lymphohistiocytosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Shanghai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Blood disorders
Beta thalassaemia
β 地中海贫血6 hospitals in Shanghai for beta thalassaemia133 hospitals in China for beta thalassaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Long-term Follow-up Study in Participants Who Received CS-101
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06479616
Age 3 years to 17 years (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
- A Long-term Follow-up Study in Participants Who Received CS-101
- Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shanghai for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Myasthenia gravis
重症肌无力Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Shanghai for myasthenia gravis89 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPrecision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT04535843
Age 0 years to 90 years (registered criteria)
Led by Huashan Hospital; 1 listed hospital as study siteShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Other diseases
Moyamoya disease
烟雾病Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Shanghai for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
- Post-anesthesia care unit delirium in children with moyamoya disease undergoing indirect revascularization: incidence and risk factors.
- Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: A retrospective study of intraoperative blood pressure.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Biliary atresia
胆道闭锁Led 21 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 9.8%.
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for biliary atresia31 hospitals in China for biliary atresia
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPreoperative Serum FGF19 in the Prognosis of Biliary Atresia
- Phase
- Not given
- Started
- 2023-10
- Registry
- NCT05848310
Age not stated (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingPreventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
- Phase
- N/A
- Started
- 2023-07
- Registry
- NCT05925309
Age 14 days to 90 days (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
- RecruitingHigh Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
- Phase
- Not given
- Started
- 2021-10
- Registry
- NCT05072626
Age Not stated to 3 months (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led21
- RNA m6A methylation regulates CDH6 to promote epithelial-to-mesenchymal transition in cholangiocytes of biliary atresia.
- Potential therapeutic effect of dimethyl fumarate on Treg/Th17 cell imbalance in biliary atresia.
- Single-cell transcription reveals hepatocyte-to-cholangiocyte reprogramming and biliary gene profile in biliary atresia.
- Establishment of Biliary Atresia Prognostic Classification System via Survival-Based Forward Clustering - A New Biliary Atresia Classification.
- Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia.
- LncRNA MEG9 Promotes Inflammation and Liver Fibrosis Through S100A9 in Biliary Atresia.
- Development and validation of a minimally invasive diagnostic model for biliary atresia using artificial intelligence.
- Incidence and outcome of biliary atresia in Shanghai, China from 2015 to 2016: a cohort study.
- NLRP3 inflammasome activation promotes liver inflammation and fibrosis in experimental biliary atresia.
- Clinical Characteristics and Prognosis of Biliary Atresia with Low Serum Matrix Metalloproteinase-7 Levels.
- Serum matrix metalloproteinase-7 for discriminating biliary atresia: a diagnostic accuracy and validation study.
- Psychological Journey and Coping Styles of Parents of Infants With Biliary Atresia: A Single-Center Qualitative Study.
- Effect of Adjuvant Steroid Therapy in Type 3 Biliary Atresia: A Single-Center, Open-Label, Randomized Controlled Trial.
- Integrative analysis implicates the significance of m6A in the liver fibrosis of biliary atresia by regulating THY1.
- Biliatresone: progress in biliary atresia study.
- Single-cell and spatial transcriptomics reveal the fibrosis-related immune landscape of biliary atresia.
- Gamma-glutamyl transpeptidase has different efficacy on biliary atresia diagnosis in different hospital patient groups: an application of machine learning approach.
- Characteristics of SOX9-positive progenitor-like cells during cholestatic liver regeneration in biliary atresia.
- Epidemiological characteristics and risk factors of biliary atresia: a case-control study.
- Preventive effect of prophylactic intravenous antibiotics against cholangitis in biliary atresia: a randomized controlled trial.
- Effect and mechanism of vitamin D activation disorder on liver fibrosis in biliary atresia.
All its trials on ClinicalTrials.gov, any status8
- Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
- Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
- High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
- A Peer Support Network System Construction for the Primary Caregivers of Children With Biliary Atresia
- Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
- Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
- Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led 3 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 5.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
6 hospitals in Shanghai for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07221669
Age 0 days to 42 days (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingA Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Registry
- NCT07554924
Age Not stated to 180 days (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.
- Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
- Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
All its trials on ClinicalTrials.gov, any status9
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
- A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
- Pediatric Spinal Muscular Atrophy (SMA) China Registry
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
- Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Other diseases
Fabry disease
法布雷病Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEvaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
- Phase
- Early phase 1
- Started
- 2024-02
- Registry
- NCT06207552
Age 7 years to 18 years (registered criteria)
Led by Children's Hospital of Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
Other diseases
Pompe disease
庞贝病Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Shanghai for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status4
- Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
- Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
- A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
- Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Shanghai for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Alport syndrome
Alport 综合征Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Shanghai for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Gaucher disease
戈谢病Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for Gaucher disease40 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Osteogenesis imperfecta
成骨不全症Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Shanghai for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hirschsprung disease
先天性巨结肠Led 4 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 2.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for Hirschsprung disease76 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Intestinal fibrosis in aganglionic segment of Hirschsprung's disease revealed by single-cell RNA sequencing.
- Serum Metabolomic Signatures of Hirschsprung's Disease Based on GC-MS and LC-MS.
- Aberrant high expression of the TET1 gene in Hirschsprung's disease.
- Skip segment Hirschsprung's disease: report of two rare cases and management.
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 2 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 3.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Majeed syndrome
Majeed 综合征Led 1 of the 3 English-language PubMed papers on Majeed syndrome with an author in mainland China, 2021–2025: 33.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shanghai for Majeed syndrome7 hospitals in China for Majeed syndrome
No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
NGLY1 deficiency
NGLY1 缺乏症Led no English-language PubMed papers on NGLY1 deficiency in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shanghai for NGLY1 deficiency2 hospitals in China for NGLY1 deficiency
No open trial on NGLY1 deficiency lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
复旦大学附属儿科医院
Children's Hospital of Fudan University
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.